Clinical Trial Detail

NCT ID NCT02187991
Title Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors US Oncology Research
Indications

triple-receptor negative breast cancer

Her2-receptor negative breast cancer

Therapies

Paclitaxel

Alisertib + Paclitaxel

Age Groups: adult senior

Additional content available in CKB BOOST